Immune checkpoint inhibitors in GBM
ConclusionsDespite the positive impact of immune checkpoint inhibitors in many cancers, only a small subset of GBM patients respond to these agents. Further research is needed to identify biomarkers of response and therapies to rationally combine with immune checkpoint inhibitors.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Clinical Trials | Neoadjuvant Therapy | Neurology | Study